Study drug for advanced liver cancer that cannot be removed
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests TTI-101, by itself and with other cancer medicines, for liver cancer that is advanced and cannot be removed by surgery. It aims to see whether the treatment can slow the cancer down and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and able to understand and sign consent.
- You must have confirmed advanced or metastatic liver cancer that cannot be surgically removed (HCC).
- Your cancer must have measurable signs on scans, and you must have an active plan that matches the trial’s prior-treatment rules.
- You must be able to swallow pills and be in fairly good physical condition (ECOG 0–1).
- Your blood tests and organ functions (liver, kidneys, blood counts) must meet minimum levels.
- If you can become pregnant or have a partner who can become pregnant, you must use effective birth control during the study and after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental oral drug (ETN101) for adults with advanced liver cancer (hepatocellular carcinoma) that has gotten worse after standard treatments or can't be treated with standard therapy. It aims to see if the drug is safe and effective.
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
This trial tests if combining two immunotherapy drugs (atezolizumab and bevacizumab) with a brain-health medicine (memantine) can help people with advanced liver cancer that isn't treatable with surgery. It aims to see if this triple therapy works better than standard options.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This trial tests a new drug called TPST-1120 combined with two standard treatments (atezolizumab and bevacizumab) for people with advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this combination works better than the standard approach alone.
This Phase 1/2 study tests new combinations of immune system medicines in people with advanced liver cancer that cannot be cured by surgery. It looks for safer treatment and signs that the medicines can shrink or control the cancer.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.